Nines develops applied machine-learning software for teleradiology, focused on prioritizing emergent head CT reviews to accelerate diagnosis and treatment. Its debut product, the Emergent Neuro Suite, analyzes head CTs to triage cytotoxic edema, hemorrhage, and mass effect. The Emergent Neuro Suite is an investigational device in the US and Nines is in discussions with the FDA about the evidence needed for a marketing application. The company positions its software as limited to imaging analysis and not a replacement for full patient evaluation or diagnosis. Nines has collaborated with top institutions and radiologists, including the Mount Sinai Health System, and has formed an advisory board of physicians from major medical centers. The company’s board includes Accel partner Steve Loughlin and 8VC founding partner Joe Lonsdale.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2019